INTEGRATED NETWORK PHARMACOLOGY, MOLECULAR DOCKING, AND IN-VITRO ANTIOXIDANT POTENTIAL OF MYRICETIN
International Journal of Drug Delivery Technology · 08.06.2026 · 16 (48s)
DOI: 10.25258/ijddt.16.48s.98 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 08.06.2026. Verfasst von Amrito Sarkar und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Oxidative stress is a major pathological factor involved in the initiation and progression of several chronic diseases, including cancer, neurodegenerative disorders, cardiovascular diseases, and metabolic dysfunction. Oxidative stress arises from an imbalance between reactive oxygen species (ROS) production and endogenous antioxidant defence systems, leading to cellular damage and impaired physiological function. Myricetin, a naturally occurring flavonol widely distributed in fruits, vegetables, and medicinal plants, has been reported to exhibit significant antioxidant and cytoprotective properties. However, its precise molecular mechanisms against oxidative stress remain incompletely understood. Therefore, the present study aimed to systematically investigate the multitarget antioxidant potential of Myricetin using an integrated approach combining network pharmacology, molecular docking, and in vitro antioxidant assays. The chemical structure of Myricetin was analyzed using ligand-based target prediction platforms, and oxidative stress-associated genes were retrieved from the GeneCards database. A total of 131 overlapping targets between Myricetin and oxidative stress were identified and used for protein–protein interaction (PPI) network construction. Topological analysis revealed key hub genes, including AKT1, EGFR, SRC, MMP9, GSK3B, and KDR. Gene Ontology enrichment indicated significant involvement in biological processes such as response to oxygen-containing compounds, protein phosphorylation, and regulation of programmed cell death. KEGG pathway analysis identified multiple significantly enriched pathways, with the PI3K-Akt signaling pathway, FoxO signaling pathway, and chemical carcinogenesis–ROS pathways being the most prominent. Molecular docking studies demonstrated strong binding affinities of Myricetin toward major hub targets, particularly KDR (−9.5 kcal/mol), AKT1 (−9.4 kcal/mol), MMP2 (−9.0 kcal/mol), CDK1 (−9.0 kcal/mol), and EGFR (−8.9 kcal/mol), with stable hydrogen bonding and hydrophobic interactions within the active sites, indicating favorable ligand–protein complex stability. In vitro antioxidant evaluation further confirmed the radical scavenging potential of Myricetin. In the DPPH assay, Myricetin showed concentrationdependent inhibition, reaching 78.8% at 100 µg/mL with an IC₅₀ of approximately 60 µg/mL. Similarly, the ABTS assay demonstrated significant radical scavenging activity, with 74.3% inhibition at 100 µg/mL. Overall, the findings suggest that Myricetin exerts potent antioxidant effects through a multitarget and multi-pathway mechanism involving regulation of oxidative stress-responsive signaling pathways and direct free radical scavenging activity.
Zitieren
APA
Sarkar, A., Gupta, M. K., & Sharma, R. (2026). INTEGRATED NETWORK PHARMACOLOGY, MOLECULAR DOCKING, AND IN-VITRO ANTIOXIDANT POTENTIAL OF MYRICETIN. International Journal of Drug Delivery Technology, 16(48s). https://doi.org/10.25258/ijddt.16.48s.98
Vancouver
Sarkar A, Gupta MK, Sharma R. INTEGRATED NETWORK PHARMACOLOGY, MOLECULAR DOCKING, AND IN-VITRO ANTIOXIDANT POTENTIAL OF MYRICETIN. International Journal of Drug Delivery Technology. 2026;16(48s). doi:10.25258/ijddt.16.48s.98
BibTeX
@article{Sarkar2026,
author = {Sarkar, Amrito and Gupta, Mahesh Kumar and Sharma, Ritu},
title = {INTEGRATED NETWORK PHARMACOLOGY, MOLECULAR DOCKING, AND IN-VITRO ANTIOXIDANT POTENTIAL OF MYRICETIN},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {48s},
doi = {10.25258/ijddt.16.48s.98}
}
EUVIMED